The efficacy of immune checkpoint inhibitors in biliary tract cancer with KRAS mutation

BACKGROUND: With a 15% incidence, KRAS is one of the most common mutations in biliary tract cancer (BTC) and is a poor prognostic factor. Immune checkpoint inhibitors (ICIs) as salvage therapy have modest activity in BTC. OBJECTIVES: There are limited data on the efficacy of ICIs according to KRAS m...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeong, Sun Young, Hong, Jung Yong, Park, Joon Oh, Park, Young Suk, Lim, Ho Yeong, Jang, Jae Yeon, Jeon, Youngkyung, Kim, Seung Tae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164250/
https://www.ncbi.nlm.nih.gov/pubmed/37163165
http://dx.doi.org/10.1177/17562848231170484

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164250/
https://www.ncbi.nlm.nih.gov/pubmed/37163165
http://dx.doi.org/10.1177/17562848231170484

Ejemplares similares